FDA Oncology Announcements

Multikinase inhibitor × Clear all

9 Announcements

FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma

Trial: CLEAR
Drugs: Lenvima (lenvatinib) · Multikinase inhibitor, Keytruda (pembrolizumab) · Anti-PD-1 antibody
Condition: Genitourinary

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma

Trial: MK-3475-775
Drugs: Keytruda (pembrolizumab) · Anti-PD-1 antibody, Lenvima (lenvatinib) · Multikinase inhibitor
Condition: Gynecologic

Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and US

Drugs: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody, LENVIMA (lenvatinib) · Multikinase inhibitor
Condition: Gynecologic

FDA approves pexidartinib for tenosynovial giant cell tumor

Trial: ENLIVEN
Drug: TURALIO (pexidartinib) · Multikinase inhibitor
Condition: Sarcoma

FDA approves lenvatinib for unresectable hepatocellular carcinoma

Drug: Lenvima (lenvatinib) · Multikinase inhibitor
Condition: Gastrointestinal

Lenvatinib in combination with Everolimus

Drugs: Lenvima (lenvatinib) · Multikinase inhibitor, everolimus · MTOR inhibitor
Conditions: EndocrineGenitourinary

Lenvatinib (Lenvima)

Drug: Lenvima (lenvatinib) · Multikinase inhibitor
Condition: Endocrine

Regorafenib

Drug: Stivarga tablets (regorafenib) · Multikinase inhibitor
Condition: Gastrointestinal

Vandetanib

Drug: Vandetanib Tablets (vandetanib) · Multikinase inhibitor
Condition: Endocrine